Jillian Savage
Interventional Pain Medicine · Spokane, WANPI 1275257081
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,563 of the $2,198 with a category attached, or 71.1%. 16 manufacturers reported payments, led by Medtronic at 45.5% of the total. Reporting peaked in 2023 at $1,093 and has fallen 73.6% since, to $288 in 2025. That places this record below the midpoint for interventional pain medicine clinicians in WA, where the typical reported total is $2,704.
Across 56 payments — averaging $39.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$1K
- Johnson & Johnson$200
- Sanofi$185
- Amgen$152
- AbbVie$142
- Si-bone, Inc.$100
- plus $419 from 10 others
What the payments were for
- Travel & lodging$53524%
- Food & beverage$1,56371%
- Education$1005%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 14 | $1,001 |
| Johnson & Johnson | 5 | $200 |
| Sanofi | 4 | $185 |
| Amgen | 5 | $152 |
| AbbVie | 8 | $142 |
| Si-bone, Inc. | 2 | $100 |
| Nalu Medical, Inc. | 3 | $69 |
| Sun Pharmaceutical Industries Inc. | 3 | $66 |
| Organon | 2 | $56 |
| UCB, Inc. | 2 | $48 |
| Regeneron Healthcare Solutions, Inc. | 2 | $47 |
| Lilly USA, LLC | 2 | $42 |
| Relievant Medsystems, Inc. | 1 | $26 |
| Biotronik NRO, Inc. | 1 | $23 |
| LEO Pharma Inc. | 1 | $23 |
| Biofrontera Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SYNCHROMEDII$503
- DUPIXENT$142
How this compares
$2,198 in reported general payments places this provider in the 45th percentile of 30 interventional pain medicine providers in Washington.
See all interventional pain medicine providers in Washington →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fluorouracil | 25 | $1,724 |
| Clobetasol Propionate | 18 | $514 |
| Triamcinolone Acetonide | 11 | $129 |
Paid to pharmacies, not to this prescriber.
Other interventional pain medicine in Spokane
- Ray BakerKirkland$1.2M
- Daniel NelsonKirkland$29K
- Kyong KimLakewood$23K
- Hyun HongOlympia$16K
- Glen DavidSeattle$14K
- Kiang Yien CheungTacoma$12K
- Diyan RazaSeattle$12K
- Kathy WangPuyallup$11K
- Allen ShohamRichland$8K
- Kashif SaeedTacoma$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.